Smither John W has filed 16 insider transactions across 3 companies since January 2024.
Most recent transaction: a grant/award of 3400 shares of NewAmsterdam Pharma Co N.V. ($NAMS) on January 07, 2026.
Activity breakdown: 2 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 7, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Smither John W | Not found | A | Ordinary Shares | 3400 | $0.00 | 10,360.0000 | 119,000,266 | 48.85% | 0.00% |
| Jan. 7, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | Smither John W | Not found | A | Option (right to buy) | 15300 | $0.00 | 15,300.0000 | 119,000,266 | 9999.99% | 0.01% |
| Aug. 27, 2025 | GENELUX Corp | $GNLX | Smither John W | Director | A | Stock Option (Right to Buy) | 28576 | $0.00 | 28,576.0000 | 34,604,296 | 9999.99% | 0.08% |
| Aug. 27, 2025 | GENELUX Corp | $GNLX | Smither John W | Director | A | Common Stock | 22283 | $0.00 | 74,994.0000 | 34,604,296 | 42.27% | 0.06% |
| Jan. 6, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Smither John W | Not found | A | Option (right to buy) | 32500 | $0.00 | 32,500.0000 | 94,358,067 | 9999.99% | 0.03% |
| Jan. 7, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | Smither John W | Not found | A | Ordinary Shares | 6960 | $0.00 | 6,960.0000 | 94,358,067 | 9999.99% | 0.01% |
| Aug. 1, 2024 | GENELUX Corp | $GNLX | Smither John W | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | GENELUX Corp | $GNLX | Smither John W | Not found | A | Common Stock | 39541 | $0.00 | 52,711.0000 | 0 | 300.24% | 0.00% |
| Aug. 1, 2024 | GENELUX Corp | $GNLX | Smither John W | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | GENELUX Corp | $GNLX | Smither John W | Not found | P | Common Stock | 6250 | $0.00 | 13,170.0000 | 0 | 90.32% | 0.00% |
| May 29, 2024 | GENELUX Corp | $GNLX | Smither John W | Not found | P | Common Stock Warrant (Right to Buy) | 6250 | $0.00 | 6,250.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2024 | Arcutis Biotherapeutics, Inc. | $ARQT | Smither John W | Chief Financial Officer | A | Common Stock | 2793 | $0.00 | 144,185.0000 | 69,305,487 | 1.98% | 0.00% |
| Feb. 13, 2024 | Arcutis Biotherapeutics, Inc. | $ARQT | Smither John W | Chief Financial Officer | A | Common Stock | 8572 | $0.00 | 152,757.0000 | 69,305,487 | 5.95% | 0.01% |
| Feb. 13, 2024 | Arcutis Biotherapeutics, Inc. | $ARQT | Smither John W | Chief Financial Officer | D | Stock Option (right to buy) | 8379 | $0.00 | 0.0000 | 69,305,487 | 100.00% | 0.01% |
| Feb. 13, 2024 | Arcutis Biotherapeutics, Inc. | $ARQT | Smither John W | Chief Financial Officer | D | Stock Option (right to buy) | 25718 | $0.00 | 0.0000 | 69,305,487 | 100.00% | 0.04% |
| Jan. 1, 2024 | NewAmsterdam Pharma Co N.V. | $NAMS | Smither John W | Not found | A | Option (right to buy) | 10000 | $0.00 | 10,000.0000 | 82,161,956 | 9999.99% | 0.01% |